MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.46−0.28 (-3.20%)
Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –
MeiraGTx price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
MeiraGTx's price to sales ratio was 2.3× on Nov 11, 2026, against 24.4× a year earlier. Over the last 5 years it ranged from 2.2× to 51.5×, with a median of 19.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.3× | −21.0 |
| 2025 | Dec 31, 2025 | 23.3× | −10.6 |
| 2024 | Dec 31, 2024 | 34.0× | +25.1 |
| 2023 | Jan 31, 2023 | 8.8× | +1.9 |
| 2022 | Dec 30, 2022 | 6.9× | −44.6 |
| 2021 | Dec 31, 2021 | 51.5× | +20.4 |
| 2020 | Dec 31, 2020 | 31.1× | – |
See a number that looks wrong?